RT Journal Article SR Electronic T1 Somatic TET2 Mutations are Associated with Giant Cell Arteritis JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.07.26.23292945 DO 10.1101/2023.07.26.23292945 A1 Robinette, Michelle L. A1 Weeks, Lachelle D. A1 Kramer, Ryan J. A1 Agrawal, Mridul A1 Gibson, Christopher J. A1 Yu, Zhi A1 Sekar, Aswin A1 Mehta, Arnav A1 Niroula, Abhishek A1 Brown, Jared T. A1 McDermott, Gregory C. A1 Reshef, Edith R. A1 Lu, Jonathan E A1 Liou, Victor D. A1 Chiou, Carolina A. A1 Natarajan, Pradeep A1 Freitag, Suzanne K. A1 Rao, Deepak A. A1 Ebert, Benjamin L. YR 2023 UL http://medrxiv.org/content/early/2023/07/31/2023.07.26.23292945.abstract AB Objective Giant cell arteritis (GCA) is an age-related vasculitis. Prior studies have identified an association between GCA and hematologic malignancies (HM). How the presence of somatic mutations which drive development of HM, or clonal hematopoiesis (CH), may influence clinical outcomes in GCA is not well understood.Methods To examine an association between CH and GCA, we analyzed sequenced exomes of 470960 UK Biobank participants for the presence of CH and used multivariable Cox regression. To examine the clinical phenotype of GCA in patients with and without somatic mutations across the spectrum of CH to HM, we performed targeted sequencing of blood samples and electronic health record review on 114 patients with GCA seen at our institution. We then examined associations between specific clonal mutations and GCA disease manifestations.Results UKB participants with CH had a 1.48-fold increased risk of incident GCA compared to UKB participants without CH. GCA risk was highest among individuals with cytopenia (HR 2.98, p =0.00178) and with TET2 mutation (HR 2.02, p =0.00116). Mutations were detected in 27.2% of our institutional GCA cohort, 3 of whom had HM at GCA diagnosis. TET2 mutations were associated with vision loss in patients with GCA (OR 4.33, p = 0.047).Conclusions CH increases risk for development of GCA in a genotype-specific fashion, with greatest risk being conferred by the presence of mutations in TET2. Somatic TET2 mutations likewise increase the risk of GCA-associated vision loss. Integration of somatic genetic testing in GCA diagnostics may be warranted in the future.Competing Interest StatementAll disclosures are unrelated to present work. L.D.W has served as a consultant/advisor for Abbvie. M.A. received consulting fees from German Accelerator Life Sciences and is a co-founder of and holds equity in iuvando Health. A.M. has served a consultant/advisory role for Third Rock Ventures, Asher Biotherapeutics, Abata Therapeutics, Flare Therapeutics, venBio Partners, BioNTech, Rheos Medicines and Checkmate Pharmaceuticals, is currently a part-time Entrepreneur in Residence at Third Rock Ventures, is an equity holder in Asher Biotherapeutics and Abata Therapeutics, and has received research funding support from Bristol-Myers Squibb. P.N. reports research grants from Allelica, Apple, Amgen, Boston Scientific, Genentech / Roche, and Novartis, personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Foresite Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine, and Novartis, scientific advisory board membership of Esperion Therapeutics, Preciseli, and TenSixteen Bio, scientific co-founder of TenSixteen Bio, equity in Preciseli and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals. S.K.F. has received consulting fees from Sling, Viridian, Immunovant, ASPEN, Medtronic, Poriferous, and WL Gore and textbook royalties from Thieme and Springer. D.A.R. has received consulting fees from Pfizer, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, HiFiBio, and Aditum. He is a member of the scientific advisory board of Scipher Medicine and has received grant support from Merck, Janssen, and Bristol-Myers Squibb. B.L.E. has received research funding from Celgene, Deerfield, Novartis and Calico and consulting fees from GRAIL. He is a member of the scientific advisory board of and a shareholder of Neomorph, TenSixteen Bio, Skyhawk Therapeutics and Exo Therapeutics.Funding StatementThis study was funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32 AR055855) (M.L.R, G.C.M.); ASH/RWJF AMFDP and Edward P. Evans Foundation for MDS (L.D.W); the Sarnoff Cardiovascular Research Foundation (R.J.K); the Deutsche Forschungsgemeinschaft (DFG, AG252/1-1) (M.A.); Knut and Alice Wallenberg Foundation (no. KAW2017.0436)(A.N.); National Institutes of Health (NIH) K07-CA263555 (C.J.G); the National Heart, Lung, and Blood Institute (5T32HL007604-37) (Z.Y.) and (T32HL116324) and Mittelman Fellowship (A.S.); the Doris Duke Charitable Foundation Physician Scientist Fellowship (M.A.); NHLBI R01HL148050 (P.N.); NIH K08-AR072791, P30-AR070253, and Burroughs Wellcome Fund Career Award in Medical Sciences (D.A.R.); NIH (R01HL082945, P01CA108631, P50CA206963, and R35CA253125), the Howard Hughes Medical Institute, and the Adelson Medical Research Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mass General Brigham IRB granted approvalI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors